13TSB_ENDANI: A pen side test for Schmallenberg virus exposure in sheep and cattle

该项目的主要目标是开发施马伦伯格病毒（SBV）的笔架侧测试，使其进入商业化阶段。农民和兽医将能够使用该测试在几分钟内确定动物是否感染了SBV，并且大大降低了中央实验室进行的现有测试的成本。该项目将使用下一代噬菌体展示技术全面筛选SBV感染动物的血清，寻找对该病毒有反应的抗体。在受感染动物中产生强烈抗体反应的病毒上的肽将被选择和制造用作血清学试验的抗原。基于这些多肽的横向流动装置测试将由目前生产几种此类测试的Forsite diagnostics开发。他们将小规模生产这些测试，以便与现有的实验室测试进行敏感性和特异性的比较。然后将对这些测试进行实地试验，以确定其易用性、在实地的性能以及可能被大型兽医实践小组使用。该项目的第二个目标是确定病毒的哪些部分在产生宿主免疫反应方面是重要的。这一信息将作为初步筛选的结果而产生，并将能够用于设计针对该病毒的下一代疫苗和测试。定于2013年发布的疫苗是一种粗制灭活病毒制剂，不太可能有任何方法将接种疫苗的动物与自然感染的动物区分开来。这可能是向非欧盟国家出口的未来要求，这意味着在不久的将来将需要更复杂的疫苗和测试策略。

This project's primary objective is to develop a pen-side test for Schmallenberg virus (SBV) to a commercialisation stage.The test will be able to be used by Farmers and Veterinarians to determine whether an animal has been infected with SBV in a matter of minutes and at a greatly reduced cost to the existing tests performed by central laboratories. The project will use next generation phage-display technology to comprehensively screen serum from SBV infected animals for antibodies that react to the virus. The peptides on the virus that produce a robust antibody response in infected animals will be selected and manufactured for used as the antigen for the serological test. Lateral flow device tests based on these peptides will be developed by Forsite diagnostics who manufacture several of these types of tests currently. They will produce a small-scale production of these tests for comparison for sensitivity and specificity against the existing laboratory-based tests. These tests will then be field trialled for ease of use, performance in the field and likely use by a large veterinary practice group. A secondary aim of the project is the identification of which parts of the virus are important in generating a host immune response. This information will be created as a result of the initial screening and will be able to be used in the design of the next generation of vaccines and tests for this virus. The vaccine due to be released in 2013 is a crude killed virus preparation and it is unlikely that there will be any way to distinguish vaccinated from naturally infected animals. This is likely to be a future requirement for export to non-EU countries meaning there will be a need for more sophisticated vaccine and test strategies in the near future.